Pre-emptive Treatments in Lupus Nephritis Patients With Serological Reactivation

• Status: Recruiting
• Trial end date: 2023-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The optimal management of asymptomatic serological reactivation (ASR) in lupus nephritis (LN) patients remained undefined. This project aims to investigate the impact of pre-emptive treatment on disease relapse in LN patients who experienced ASR.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Hong Kong
• Collaborator: United Christian Hospital
• Treatments: Immunosuppressive Agents; Prednisolone

Criteria

Inclusion Criteria:

• Patients with biopsy-proven lupus nephritis who experienced an episode of Asymptomatic Serological Flare (ASF) as defined by:

1. Increase in anti-dsDNA to >100 IU/mL, with or without drop in serum complement levels OR

2. Increase in anti-dsDNA to higher than the normal range and more than two times of the preceding value, with or without drop in serum complement levels

AND

3. Absence of renal or systemic manifestation of SLE.

Exclusion Criteria:

1. Patients who cannot provide informed consent.

2. Patients whom the clinicians opined to have excessively high risk of infection or malignancy.

3. Patients who are pregnant or lactating.